Off-label Use of Long-Acting Injectable Antiretroviral Therapy: A Single Center Retrospective Review of Youth Living With HIV With Detectable HIV RNA Starting Injectable Therapy

被引：5

作者：

Rousseau, Alison ^{[1
]}

McGrath, Eric ^{[2
]}

Benjamins, Laura ^{[3
]}

Cockern, Salome ^{[4
]}

Meade, Jill ^{[4
]}

Houston, Keshaum ^{[4
]}

Breaux, Melina ^{[4
]}

Secord, Elizabeth ^{[5
]}

机构：

[1] Wayne State Univ, Sch Med WSUSOM, Detroit, MI USA

[2] Div Pediat Infect Dis, WSUSOM, Detroit, MI USA

[3] Div Adolescent Med, WSUSOM, Detroit, MI USA

[4] Dept Pediat, WSUSOM, Detroit, MI USA

[5] Div Chief Allergy & Immunol, WSUSOM, Wayne Pediat 400 Mack Ave, Detroit, MI 48201 USA

来源：

JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY | 2024年 / 13卷 / 05期

关键词：

adherence; HIV; HIV plus youth; injectable antiretrovirals; perinatal; RILPIVIRINE; ADOLESCENTS; ADHERENCE; ADULTS;

D O I：

10.1093/jpids/piae033

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Nineteen youth living with HIV (YLWH) opted for injectable cabotegravir and rilpivirine without oral lead in and without achieving an undetectable HIV viral load (VL) for the 3 months prior to initiation. All achieved undetectable status within 3 months (3 injections) and maintained an undetectable status through 6-12 months of therapy. Nineteen youth living with HIV (YLWH) started injectable cabotegravir and rilpivirine without oral lead in and without achieving an undetectable HIV VL for the 3 months prior to initiation. All achieved undetectable status within 3 months (3 injections) maintaining undetectable status 6-12 months into therapy.

引用

页码：285 / 287

页数：3

共 12 条

[1] Rare case of rilpivirine-induced severe allergic hepatitis [J].

Ahmed, Yasir ;

Siddiqui, Wajid ;

Enoch, Caroline B. ;

Albrecht, Helmut ;

Bookstaver, P. Brandon .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (02) :484-486

[2] Randomized Controlled Trial of a Remote Coaching mHealth Adherence Intervention in Youth Living with HIV [J].

Amico, K. Rivet ;

Lindsey, Jane C. ;

Hudgens, Michael ;

Dallas, Ronald ;

Horvath, Keith J. ;

Dunlap, Amanda ;

Goolsby, Rachel ;

Johnson, Megan Mueller ;

Heckman, Barbara ;

Crawford, Jessica ;

Secord, Elizabeth ;

Purswani, Murli ;

Reirden, Danial ;

Rathore, Mobeen ;

Robinson, Lisa-Gaye ;

Gaur, Aditya H. .

AIDS AND BEHAVIOR, 2022, 26 (12) :3897-3913

[3]

[Anonymous], Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents

[4] Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir plus rilpivirine (LATTE-2) in the United States and Spain [J].

Kerrigan, Deanna ;

Mantsios, Andrea ;

Gorgolas, Miguel ;

Montes, Maria-Luisa ;

Pulido, Federico ;

Brinson, Cynthia ;

deVente, Jerome ;

Richmond, Gary J. ;

Beckmam, Sarah W. ;

Hammond, Paige ;

Margolis, David ;

Murray, Miranda .

PLOS ONE, 2018, 13 (01)

[5]

Casado JL, 2013, AIDS REV, V15, P139

[6] Medication Adherence in Children and Adolescents with HIV Infection: Associations with Behavioral Impairment [J].

Malee, Kathleen ;

Williams, Paige ;

Montepiedra, Grace ;

McCabe, Marie ;

Nichols, Sharon ;

Sirois, Patricia A. ;

Storm, Deborah ;

Farley, John ;

Kammerer, Betsy .

AIDS PATIENT CARE AND STDS, 2011, 25 (03) :191-200

[7] Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial [J].

Margolis, David A. ;

Gonzalez-Garcia, Juan ;

Stellbrink, Hans-Juergen ;

Eron, Joseph J. ;

Yazdanpanah, Yazdan ;

Podzamczer, Daniel ;

Lutz, Thomas ;

Angel, Jonathan B. ;

Richmond, Gary J. ;

Clotet, Bonaventura ;

Gutierrez, Felix ;

Sloan, Louis ;

St Clair, Marty ;

Murray, Miranda ;

Ford, Susan L. ;

Mrus, Joseph ;

Patel, Parul ;

Crauwels, Herta ;

Griffith, Sandy K. ;

Sutton, Kenneth C. ;

Dorey, David ;

Smith, Kimberly Y. ;

Williams, Peter E. ;

Spreen, William R. .

LANCET, 2017, 390 (10101) :1499-1510

[8]

Moore CB., CROI 2022

[9] Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study [J].

Overton, Edgar T. ;

Richmond, Gary ;

Rizzardini, Giuliano ;

Jaeger, Hans ;

Orrell, Catherine ;

Nagimova, Firaya ;

Bredeek, Fritz ;

Deltoro, Miguel Garcia ;

Swindells, Susan ;

Andrade-Villanueva, Jaime Federico ;

Wong, Alexander ;

Khuong-Josses, Marie-Aude ;

Van Solingen-Ristea, Rodica ;

van Eygen, Veerle ;

Crauwels, Herta ;

Ford, Susan ;

Talarico, Christine ;

Benn, Paul ;

Wang, Yuanyuan ;

Hudson, Krischan J. ;

Chounta, Vasiliki ;

Cutrell, Amy ;

Patel, Parul ;

Shaefer, Mark ;

Margolis, David A. ;

Smith, Kimberly Y. ;

Vanveggel, Simon ;

Spreen, William .

LANCET, 2020, 396 (10267) :1994-2005

[10] Comparison of Adherence to Medications and to Clinic Visits between HIV Infected Adolescents and Young Adults: Perinatally versus Behaviorally Infected [J].

Reddy, S. ;

Seth, D. ;

Malhotra, G. ;

Zeballos-chavez, R. ;

Secord, E. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (02) :AB79-AB79

← 1 2 →